Literature DB >> 23829941

Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas--is it indicated?

Lucinda S Liu1, Daniel Sokoloff, Richard J Antaya.   

Abstract

In recent years, oral propranolol has risen from serendipitous discovery to first-line, albeit off-label, therapy for infantile hemangiomas (IHs). This retrospective study explored the utility of a 24-hour hospitalization for the initiation of propranolol therapy in children with problematic IHs by evaluating the effects of systemic propranolol on hemodynamics and blood sugar levels. Thirty-one children were admitted to the hospital to begin oral propranolol at a dose of 2 mg/kg/per day. Heart rate (HR), blood pressure (BP), and blood glucose (BG) measurements were obtained at baseline and 1 to 3 hours before and after each dose of propranolol. No caregivers reported any adverse effects during the hospitalization. On average, HR decreased by 5 beats per minute (bpm) (p < 0.01) and systolic BP decreased by 4 mmHg (p < 0.01) after propranolol administration. There was no statistically significant change in diastolic BP or BG with propranolol therapy. Over the first three doses of propranolol we saw statistically significant attenuation of the effects of propranolol on HR, with HR approaching baseline values during the hospitalization (p = 0.04). We did not see statistically significant changes in BP over the course of three doses of propranolol. This study suggests that 24-hour hospitalization with hemodynamic monitoring may not be necessary for safe initiation of propranolol therapy in otherwise healthy infants. Parental education on frequent feedings to decrease the chance of hypoglycemia may be as effective as 24-hour hospitalization.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23829941     DOI: 10.1111/pde.12182

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  3 in total

1.  Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants.

Authors:  Giovanni Frongia; Ji-Oun Byeon; Raoul Arnold; Arianeb Mehrabi; Patrick Günther
Journal:  World J Pediatr       Date:  2018-05-23       Impact factor: 2.764

Review 2.  Treatment of infantile haemangiomas: recommendations of a European expert group.

Authors:  Peter H Hoeger; John I Harper; Eulalia Baselga; Damien Bonnet; Laurence M Boon; Marta Ciofi Degli Atti; Maya El Hachem; Arnold P Oranje; Agneta Troilius Rubin; Lisa Weibel; Christine Léauté-Labrèze
Journal:  Eur J Pediatr       Date:  2015-05-29       Impact factor: 3.183

3.  Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome.

Authors:  Gerilyn M Olsen; Leanna M Hansen; Nicole S Stefanko; Erin Mathes; Katherine B Puttgen; Megha M Tollefson; Christine Lauren; Anthony J Mancini; Catherine C McCuaig; Ilona J Frieden; Denise Adams; Eulalia Baselga; Sarah Chamlin; Deepti Gupta; Peter Frommelt; Maria C Garzon; Kimberly Horii; Justyna Klajn; Mohit Maheshwari; Brandon Newell; Henry L Nguyen; Amy Nopper; Julie Powell; Dawn H Siegel; Beth A Drolet
Journal:  JAMA Dermatol       Date:  2020-02-01       Impact factor: 10.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.